2. GPCR/G Protein Protein Tyrosine Kinase/RTK Stem Cell/Wnt MAPK/ERK Pathway Immunology/Inflammation
  3. Chemerin Receptor Syk ERK Src p38 MAPK P-selectin
  4. Chemerin15

Chemerin15 is an anti-inflammatory peptide derived from Chemerin. Chemerin15 binds to ChemR23. Chemerin15 inhibits TNFα-induced activation of Syk, ERK and Src kinases. Chemerin15 increases the expression of p-p38 mRNA and protein. Chemerin15 mediates phagocytosis, resolution of inflammation, CD62L shedding and downregulation of PSGL-1 expression in macrophages and microglia. Chemerin15 inhibits neutrophil-mediated vascular inflammation and myocardial ischemia-reperfusion injury via ChemR23. Chemerin15 enhances microglial phagocytosis, thereby alleviating cerebral ischemia-reperfusion injury.

For research use only. We do not sell to patients.

Custom Peptide Synthesis

Chemerin15

Chemerin15 Chemical Structure

CAS No. : 1020407-90-2

Size Price Stock Quantity
1 mg In-stock
5 mg In-stock
10 mg In-stock
25 mg In-stock
50 mg   Get quote  
100 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Chemerin15 Related Antibodies

Top Publications Citing Use of Products

View All Chemerin Receptor Isoform Specific Products:

View All Isoforms
ChemR23/CMKLR1

View All ERK Isoform Specific Products:

View All Isoforms
ERK ERK1 ERK2 ERK5 ERK8

View All Src Isoform Specific Products:

View All Isoforms
Lck Fyn Blk Fgr Hck Lyn Yes SRC-3

View All p38 MAPK Isoform Specific Products:

View All Isoforms
p38 MAPK Akt1 p38α p38β MAPK13 p38δ p38γ

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Chemerin15 is an anti-inflammatory peptide derived from Chemerin. Chemerin15 binds to ChemR23. Chemerin15 inhibits TNFα-induced activation of Syk, ERK and Src kinases. Chemerin15 increases the expression of p-p38 mRNA and protein. Chemerin15 mediates phagocytosis, resolution of inflammation, CD62L shedding and downregulation of PSGL-1 expression in macrophages and microglia. Chemerin15 inhibits neutrophil-mediated vascular inflammation and myocardial ischemia-reperfusion injury via ChemR23. Chemerin15 enhances microglial phagocytosis, thereby alleviating cerebral ischemia-reperfusion injury[1][2][3].

In Vitro

Chemerin15 (0.1 pM-1 nM; 45 min) enhances the phagocytic rate and capacity of wild-type mouse peritoneal macrophages against zymosan and opsonized zymosan in vitro in a ChemR23- and Syk-dependent manner, with its optimal active concentration being 10 pM[1].
Chemerin15 (0.01 pM-10 pM; 45 min) enhances the non-inflammatory phagocytosis of apoptotic Jurkat cells by peritoneal macrophages from wild-type mice, with an optimal active concentration of 1 pM[1].
Chemerin15 (500 ng/mL; 30 min) enhances the phagocytosis of pHrodo Red Zymosan bioparticles by OGD-treated BV2 mouse microglia via the ChemR23 receptor[2].
Chemerin15 (500 ng/mL; 30 min) promotes phagocytosis of HT-22 mouse hippocampal neurons by OGD-treated RFP-BV2 mouse microglia[2].
Chemerin15 (500 ng/mL; 30 min) upregulates phagocytosis-related genes and activates the p38 MAPK signaling pathway in OGD-treated BV2 mouse microglia via the ChemR23 receptor[2].
Chemerin15 (500 ng/mL; 30 min) upregulates the expression of phosphorylated p38 MAPK protein in OGD-treated BV2 mouse microglial cells via the ChemR23 receptor[2].
Chemerin15 (0.1-1000 pM; 20 min) induces CD62L shedding and reduces PSGL-1 expression in human resting neutrophils, with 10 pM Chemerin15 causing 50% CD62L shedding and a 25% downregulation of PSGL-1 expression[3].
Chemerin15 (10-1000 pM; 10 min) inhibits TNFα-induced adhesion and spreading of human neutrophils to immobilized ICAM-1 via a ChemR23-dependent mechanism, with an inhibition rate of 65% at 10 pM[3].
Chemerin15 (10 pM) inhibits TNFα-induced activation of Syk, ERK and Src kinases in human neutrophils, with inhibition rates of 69%, 80% and 61% on pSyk, pErk and pSrc activities, respectively[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemerin15 Related Antibodies

Western Blot Analysis[2]

Cell Line: BV2 mouse microglial cells
Concentration: 500 ng/mL
Incubation Time: 30 min (pre-incubated before OGD)
Result: Significantly increased both p-p38 mRNA and protein expression in BV2 cells compared to the OGD-only group.
Inhibited the increase in p-p38 expression when co-treated with α-NETA, reducing levels toward those seen in the OGD-only group.
In Vivo

Chemerin15 (8 pg/mouse; i.p.; single dose) enhances macrophage-mediated clearance of zymosan and apoptotic neutrophils in a zymosan-induced peritonitis model, reducing apoptotic and necrotic cell populations at the inflammatory site[1].
Chemerin15 (0.3 ng/kg; intranasal; after reperfusion) enhances microglial phagocytosis, reduces DAMP and ROS levels, decreases infarct volume by ~40%, and improves neurological function in mice with cerebral ischemia-reperfusion injury via the ChemR23/p38 MAPK pathway[2].
Chemerin15 (0.1-100 pg/mouse; i.p., i.v.) inhibits TNFα-induced mesenteric microvascular inflammation in mice through ChemR23, with prophylactic administration reducing neutrophil adhesion by 70% and extravasation by 60% at 10 pg/mouse, and therapeutic administration causing ~50% detachment of adherent neutrophils within 3.4 minutes[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: C57BL/6J mice (zymosan-induced peritonitis)[1]
Dosage: 8 pg/mouse (0.32 ng/kg)
Administration: i.p.; single dose
Result: Enhanced macrophage zymosan clearance by 38% at 1 hour post-zymosan challenge, increasing the percentage of zymosan+F4/80+ peritoneal exudate cells from 23% to 34%; enhanced clearance was also observed at 2 and 4 hours.
Enhanced Ly6G+ apoptotic neutrophil phagocytosis by 88% at 8 hours post-zymosan challenge, with enhanced clearance also seen at 2, 4, and 16 hours.
Reduced the percentage of apoptotic peritoneal exudate cells by 31% (from 18% to 12%) and necrotic cells by 53% (from 4% to 1.9%) at 4 hours post-zymosan challenge.
Animal Model: C57Bl/6J mice; Sv129Ev wild-type mice; Sv129Ev ChemR23 - / - mice (vascular inflammation induced by intraperitoneal TNFα)[3]
Dosage: 0.1 pg/mouse; 10 pg/mouse; 100 pg/mouse
Administration: i.p. (prophylactic); i.v. (therapeutic)
Result: Increased leukocyte rolling velocities fourfold, reduced neutrophil adhesion by 70%, and reduced neutrophil extravasation by 60% at 10 pg/mouse (prophylactic).
Elicited rapid detachment of ~50% of adherent neutrophils from inflamed venular endothelium, with an average onset of 3.4 minutes post-injection at 10 pg/mouse (therapeutic).
Showed maximal efficacy at 10 pg/mouse and 100 pg/mouse (prophylactic).
Accelerated return to baseline rolling velocities while reducing adhesion and emigration (prophylactic).
No effects were observed in ChemR23 - / - mice.
Molecular Weight

1605.70

Formula

C75H100N18O22
CAS No.
Appearance

Solid

Color

White to off-white

Sequence

Ala-Gly-Glu-Asp-Pro-His-Gly-Tyr-Phe-Leu-Pro-Gly-Gln-Phe-Ala
Sequence Shortening

AGEDPHGYFLPGQFA
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Sealed storage, away from moisture

Powder -80°C 2 years
-20°C 1 year

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Solvent & Solubility
In Vitro: 

DMSO : 100 mg/mL (62.28 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 0.6228 mL 3.1139 mL 6.2278 mL
5 mM 0.1246 mL 0.6228 mL 1.2456 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Calculation results:
Working solution concentration: mg/mL
Purity & Documentation
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 0.6228 mL 3.1139 mL 6.2278 mL 15.5695 mL
5 mM 0.1246 mL 0.6228 mL 1.2456 mL 3.1139 mL
10 mM 0.0623 mL 0.3114 mL 0.6228 mL 1.5570 mL
15 mM 0.0415 mL 0.2076 mL 0.4152 mL 1.0380 mL
20 mM 0.0311 mL 0.1557 mL 0.3114 mL 0.7785 mL
25 mM 0.0249 mL 0.1246 mL 0.2491 mL 0.6228 mL
30 mM 0.0208 mL 0.1038 mL 0.2076 mL 0.5190 mL
40 mM 0.0156 mL 0.0778 mL 0.1557 mL 0.3892 mL
50 mM 0.0125 mL 0.0623 mL 0.1246 mL 0.3114 mL
60 mM 0.0104 mL 0.0519 mL 0.1038 mL 0.2595 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Chemerin15 Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Chemerin151020407-90-2Chemerin 15Chemerin-15Chemerin ReceptorSykERKSrcp38 MAPKP-selectinSpleen tyrosine kinaseExtracellular signal regulated kinasesCD62β1/β2 integrinsmicroglial cellsneutrophilsERK kinaseSrc kinasemacrophagescerebral ischemia-reperfusion injuryChemR23Inhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Chemerin15
Cat. No.:
HY-P6442
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (252 KB) Français - FR (252 KB) Deutsch - DE (252 KB) Norwegian - NO (252 KB) Español - ES (252 KB) Swedish - SV (252 KB) Italian - IT (252 KB) Korean - KR (252 KB) Portuguese - PT (252 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.